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Abstract
Background: The integration of different ‘omics’ technologies has already been shown in several in vivo studies to
offer a complementary insight into cellular responses to toxic challenges. Being interested in developing in vitro
cellular models as alternative to animal-based toxicity assays, we hypothesize that combining transcriptomics and
metabonomics data improves the understanding of molecular mechanisms underlying the effects caused by a
toxic compound also in vitro in human cells. To test this hypothesis, and with the focus on non-genotoxic
carcinogenesis as an endpoint of toxicity, in the present study, the human hepatocarcinoma cell line HepG2 was
exposed to the well-known environmental carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD).
Results: Transcriptomics as well as metabonomics analyses demonstrated changes in TCDD-exposed HepG2 in
common metabolic processes, e.g. amino acid metabolism, of which some of the changes only being confirmed if
both ‘omics’ were integrated. In particular, this integrated analysis identified unique pathway maps involved in
receptor-mediated mechanisms, such as the G-protein coupled receptor protein (GPCR) signaling pathway maps, in
which the significantly up-regulated gene son of sevenless 1 (SOS1) seems to play an important role. SOS1 is an
activator of several members of the RAS superfamily, a group of small GTPases known for their role in
carcinogenesis.
Conclusions: The results presented here were not only comparable with other in vitro studies but also with in vivo
studies. Moreover, new insights on the molecular responses caused by TCDD exposure were gained by the cross-
omics analysis.
Background
Presently, where the current testing strategy for identify-
ing carcinogenic properties of novel chemicals has been
designed to effectively capture genotoxic carcinogens,
for the identification of important class of non-geno-
toxic carcinogens no suitable short-term test model,
neither in vivo nor in vitro, is available yet. Till date, dis-
covery of non-genotoxic carcinogenicity is completely
depending on the two-year chronic rodent bioassays.
These in vivo assays not only require a large number of
animals, are costly, laborious, and time-consuming, but
also cause many false-positive responses and their rele-
vance towards human is questionable. Therefore, alter-
native assays are needed.
Transcriptomics has been well established in toxicoge-
nomics research [1] and initial studies have indicated
that gene expression profiling in both in vivo and in
vitro systems is of value for predicting genotoxicity and
carcinogenicity. As the liver is the major target organ
for non-genotoxic carcinogens, short term in vivo stu-
dies have been targeted towards rat liver and these have
generated promising gene expression profiles capable of
reliably predicting non-genotoxic carcinogenesis [2-4].
Furthermore, promising results have been achieved in
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gens from non-genotoxic carcinogens in the human
liver cell line HepG2 [5,6]. The genes identified in these
short term in vivo and HepG2 studies are involved in
processes related to cell cycle, cell signaling, (anti-)apop-
tosis, oxidative DNA/protein damage response, prolifera-
tion, cancer, transcription and protein synthesis. In
addition, results of in vivo rodent studies, in which a
single non-genotoxic carcinogen is examined, e.g. WY-
14,643 [7] and 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) [8-10], indicated changes in amino acid meta-
bolism, lipid metabolism and oxidative stress mediated
through ligand-activated receptors (e.g. aryl hydrocarbon
receptor (AHR), peroxisome proliferator activated recep-
tor (PPAR), pregnane × receptor (PXR; NR1I2), consti-
tutive androstane receptor (CAR; NR1I3)).
Because reported transcriptomic changes induced by
TCDD and other non-genotoxic carcinogens in short term
in vivo studies, referred to the possibility that the endogen-
ous metabolism is affected, we decided to particularly
explore the added value of metabonomics analysis in iden-
tifying molecular responses in vitro caused by non-geno-
toxic carcinogens. Metabonomics is defined as the study
of metabolic responses to drugs, environmental changes
and diseases http://www.medterms.com/script/main/art.
asp?articlekey=38634. It combines the application of analy-
tical technologies (e.g. nuclear magnetic resonance spec-
troscopy (NMR), mass spectrometry (MS)) for metabolic
profiling with multivariate statistical methods. In general,
metabonomics is considered to be complementary to tran-
scriptomics and proteomics [11]. However, this technique
shows some distinct features in comparison to these other
‘omics’ technologies: a) It analyses the end point in a series
of changes following exposure to a chemical compound; b)
many of the metabolites have a known function; c)
changes are detectable intracellularly as well as in extracel-
lular fluids [12]. Various studies illustrate the applications
of metabonomics in e.g. toxic risk assessment, biomarker
discovery, and studies on toxic mechanisms [13,14], but so
far have been performed in vivo.
Such in vivo studies have also demonstrated that the
integration of different ‘omics’ technologies offers a
complementary insight into cellular responses to toxic
processes [15-19]. For example, in the study of Coen et
al. [15] the integration of transcriptomics and metabo-
nomics provided new insight into the toxic conse-
quences for the well-studied therapeutic agent
acetaminophen in mice. In adition, Heijne et al.[ 1 7 ]
showed that the cross-omicsa n a l y s i sp r o v i d e sn e w
insight in the mechanisms of hepatotoxicity in rats
exposed to bromobenzene, and also appears to be more
sensitive than conventional techniques for indicating
induced liver injury. We, therefore, hypothesize that
combining of transcriptomics and metabonomics data
improves the understanding of molecular responses to
non-genotoxic carcinogens also in in vitro cellular mod-
els, thus potentially contributing to developing cellular
assays which are capable of predicting non-genotoxic
carcinogenesis in vivo [20]. To test this hypothesis, the
human hepatocarcinoma cell line HepG2 was exposed
to the well-known environmental pollutant TCDD.
TCDD is considered a non-genotoxic human carcinogen
(IARC group 1 classification) that activates AHR and
induces a broad spectrum of toxic responses including
death, immunosuppression, carcinogenicity, and impaired
reproduction and development [21,22]. TCDD has a long
half-life of 5-10 years in human beings as a result of its
high lipophilicity and shows little or no metabolism [23].
The past decades, its effect on the endogenous metabolism
in vivo as well as in vitro has been explored, showing
changes in e.g. amino acid metabolism, lipid metabolism
and polyamine synthesis [8-10,24-29].
HepG2 was chosen as in vitro cell model since it has
frequently been applied in toxicogenomics studies
[5,6,30-32]. These cells possess a liver-like enzyme pat-
tern [33], expressing many phase I, II and III drug meta-
bolizing enzymes and are competent for regulating these
enzymes by ligand-activated transcription factors
[34-38]. Furthermore, its metabolizing capacities are evi-
dent [39], albeit that metabolic activation does not play
a role for TCDD. Furthermore, we have previously
observed changes in expression of genes related to the
amino acid and lipid metabolism as well as other meta-
bolic processes especially after 48 h of exposure to
TCDD in HepG2 [40], which underlines the relevance
of this hepatocellular model for the present study.
Results
Transcriptomics
The log2 ratios of the filtered data set were used for the
selection of significantly modulated DEGs. In total 1,048
DEGs (590 up-regulated; 458 down-regulated) were
identified, of which 873 modifications of gene expres-
sion levels (505 up-regulated; 369 down-regulated)
appeared statistically significant (p value < 0.05; False
discovery rate (FDR) < 0.08). Expression data of the
1,048 genes are included as additional file 1.
The significantly modulated DEGs were compared
with 62 genes affected by TCDD in both rat and mouse
hepatic tissue from the studies of Boverhof et al. [8] (32
genes) and Boutros et al. [41] (33 genes). From these 62
genes 18 were common between the rodent studies and
our results. Gene expression changes were in the same
direction for 13 common genes, which were mainly
involved in (oxidative) stress and xenobiotic responses
(e.g. cytochrome P450 (CYP) 1A1, CYP1A2, CYP1B1,
NAD(P)H quinone oxidoreductase (NQO1), heme oxy-
genase (decycling) 1 (HMOX1)).
Jennen et al. BMC Systems Biology 2011, 5:139
http://www.biomedcentral.com/1752-0509/5/139
Page 2 of 13Metabonomics
T h er e s u l t so ft h em e t a b o n o m i c sa n a l y s i sh a v ep r e -
viously been described by Ruiz-Aracama et al. [42] and
are summarized below.
Analysis of the apolar fraction
The apolar fractions of the cells were first analyzed by
1H NMR. From this analysis the main effects in HepG2
cells exposed to TCDD compared to the control were
the decrease in the content of triglycerides, cholesterol
ester and fatty acids.
GC-MS analysis was also conducted on the apolar
fraction of the cells, in order to get better idea of the
effect of TCDD on the fatty acid composition of the
samples. After exposure to TCDD the level of most fatty
acids was decreased. This was even more distinct in the
case of shorter chain fatty acids, such as those with 12,
14 and 16 carbon atoms, which were more affected than
different isomers of fatty acids of higher chain lengths.
Table 1 shows the final results of the analysis of the
apolar fraction.
Analysis of the polar fraction
The polar fractions extracted from the exposed cells
were first analysed by
1H NMR followed by LC-MS. Dif-
ferences between the polar fraction of the cells exposed
to TCDD and those exposed to the control clearly
showed a decrease of most amino acids as well as some
amino acid conjugates, polyamines and nucleotides. Sig-
nal intensities of taurine, citrate, reduced glutathione
(GSH), and oxidized glutathione (GSSG), increased with
the TCDD treatment. The log2 ratios of all polar meta-
bolites found in this study are shown in Table 2.
Pathway analysis and data integration
The significantly modulated DEGs and metabolites were
further analyzed with respect to their involvement in
different pathway maps. For this purpose, these genes
and metabolites were uploaded into MetaCore. In this
section significantly modulated maps (p value < 0.05
and at least two genes or metabolites present) are
further described. FDRs were < 0.4 and < 0.15 for the
trancriptomics and metabonomics based maps,
Table 1 Significantly modulated metabolites from the
apolar fraction of TCDD-exposed HepG2 (P < 0.01)
a
Fatty acid
b Log2 ratio of TCDD/DMSO
c
C12:0 -0.32
C14:0 -0.51
C14:1* -0.51
C14:1* -1.74
C16:1 (n-6) -0.74
C16:1 (n-9) -0.74
C17:0 0.26
C18:0 0.38
C18:1 (n-9) -0.32
C18:1* -0.51
C18:2* -0.51
C18:2* -0.74
C18:2* 0.38
C18:2* -0.74
C18:2* -0.74
C20:1 -0.32
C20:2* -0.51
C20:2* -0.51
C20:3* -0.32
C20:3* -0.74
C22:2 -0.74
C22:3 -0.51
Other
Triglycerides -1.00
Cholesteryl ester -0.51
aadapted from Ruiz-Aracama et al. [42]
bisomers, which cannot be distinguished from each other, are indicated by an
asterisk (*)
clog2 ratios between TCDD and vehicle control (DMSO).
Table 2 Significantly modulated metabolites from the
polar fraction of the TCDD-exposed HepG2 (P < 0.01)
a
Metabolite Log2 ratio
b
(
1H NMR)
Log2 ratio
b
(LC-MS)
Leucine, Isoleucine -0.51 –
Valine -0.51 –
Alanine -0.51 –
N-acetylaspartate -0.51 -0.51
Glutamate -0.32 –
Glutamine -0.51 –
Glycine -0.51 –
Aspartate -0.51 –
Serine -0.51 –
Tyrosine -0.74 -1.32
Proline – -1.00
Tryptophan – -0.32
Lactate -1.00 –
Spermidine – -2.32
N1-acetyl-spermidine – -0.74
Panthotenic acid – -0.74
Creatine/Phosphocreatine -0.51 –
Propyonylcarnitine – -0.51
Butyrylcarnitine – -0.74
Nucleotides (AMP, ADP, ATP and UMP) -1.74 to -0.74 –
UMP – -0.49
AMP – -0.51
Oxidized glutathione 0.38 0.38
Reduced glutathione 0.68 0.26
Taurine 0.49 –
Citrate 0.58 0.77
aadapted from Ruiz-Aracama et al. [42]
blog2 ratios between TCDD and vehicle control (DMSO).
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number of maps are listed in Table 3. A complete list of
significantly modulated maps per MetaCore analysis can
be found as part of additional file 2.
The most prominent transcriptomics-based maps were
involved in metabolic processes with amino acid meta-
bolism on top followed by lipid metabolism, steroid
metabolism, metabolism of mediators and vitamin and
cofactor metabolism. From the metabonomics-based
maps processes involved in metabolism (i.e. amino acid,
lipid and vitamin and cofactor metabolism) were most
strongly deregulated as wells as G-protein coupled
receptor protein (GPCR) signaling.
Comparison between transcriptomics- and metabo-
nomics-based maps reveals an overlap consisting of 14
maps that were mainly involved in amino acid metabo-
lism, but also GSH metabolism (cellular process: Vita-
min and cofactor metabolism) was jointly identified by
transcriptomics and metabonomics analysis. In addi-
tional file 2 these common maps are indicated.
In addition to the analyses of the separate gene and
metabolite lists the significant DEGs and metabolites
analyzed after 48 h of exposure, were actually combined
for the purpose of an integrated analysis of transcrip-
tomics and metabonomics data. This analysis resulted in
164 significantly modulated pathway maps (FDR < 0.23)
of which 73 maps contain both significant DEGs as well
as significantly modulated metabolites. The cellular pro-
cesses in which these 73 pathway maps are involved are
presented in Table 3.
Cross-omics analysis revealed amino acid metabolism,
lipid metabolism, GPCR signaling, Vitamin and cofactor
metabolism and transcription to be the cellular pro-
cesses most dominantly affected in HepG2 by TCDD
exposure. For some processes, this was also demon-
strated by either transcriptomics or metabonomics
Table 3 Cellular processes and pathway maps from MetaCore analyses
Input data for MetaCore
a Total number of maps Cellular process (number of maps)
b
Transcripts 54 Amino acid metabolism (14)
Carbohydrates metabolism (2)
Lipid metabolism (11)
Metabolism of mediators (6)
Small GTPase mediated signal transduction (1)
Steroid metabolism (9)
Transcription (3)
Vitamin and cofactor metabolism (5)
Other (2)
Metabolites 58 Amino acid metabolism (21)
Apoptosis (2)
G-protein coupled receptor protein signaling (10)
Immune response (1)
Lipid metabolism (5)
Nucleotide metabolism (3)
Transcription (1)
Vitamin and cofactor metabolism (4)
Other (11)
Integrated data 73 Amino acid metabolism (21)
Apoptosis (1)
G-protein coupled receptor protein signaling (14)
Immune response (2)
Intracellular receptor-mediated signaling pathway (2)
Lipid metabolism (7)
Metabolism of mediators (3)
Nucleotide metabolism (3)
Small GTPase mediated signal transduction (1)
Transcription (4)
Vitamin and cofactor metabolism (4)
Other (11)
aThe significantly modulated genes, metabolites and integrated data of the TCDD-exposed HepG2 were used as input.
bCellular processes with at least four maps are high-lighted in bold
Jennen et al. BMC Systems Biology 2011, 5:139
http://www.biomedcentral.com/1752-0509/5/139
Page 4 of 13analysis (Table 3). Most importantly, the integrated ana-
lysis uniquely identified 16 pathway maps which are
mainly related to GPCR signaling (9 maps), intracellular
receptor-mediated signaling (2 maps) and transcription
(2 maps). A complete list of modulated maps retrieved
by integrated analysis in MetaCore containing both sig-
nificant DEGs as well as significantly modulated meta-
bolites is provided as additional file 3.
Discussion
For integrating read-outs from different ‘omics’ plat-
forms, i.e. transcriptomics, proteomics and metabo-
nomics, in general, there is no lack of tools that are
capable of visualizing data in a biological network con-
text [43]. However, tools that directly integrate e.g. tran-
scriptomics and metabonomics data in a pathway
ranking analysis are available only to a limited extent. In
this study, MetaCore was used for performing such an
integrative analysis based on a combined list of tran-
scriptomics and metabonomics data from TCDD-
exposed HepG2 cells. We, thereby, hypothesize that
combining of these ‘omics’ data will improve the under-
standing of molecular responses caused by TCDD in
this in vitro heptocellular model. This cross-omics ana-
lysis demonstrated specific involvement of pathways
related to receptor-mediated processes, cell signaling
and endogenous metabolism.
Although different mechanisms may be involved in
the carcinogenic action of non-genotoxic compounds,
receptor-mediated processes are definitely eligible as
possible mechanisms for non-genotoxic carcinogenicity
of TCDD [44]. As an AHR-ligand, TCDD induces the
transcription of CYP1A1, CYP1B1 and NQO1, which
are all significantly up-regulated in this study, and this
may lead to the generation of reactive oxygen species
(ROS; includes superoxide anion and hydrogen perox-
ide) and thereby oxidative stress/DNA damage [45-47].
The latter was identified as a specific process for non-
genotoxic carcinogenicity [47]. In the study by Knerr et
al. [45] a slight increase of oxidative DNA damage was
measured after incubation of HepG2 cells with TCDD.
Furthermore, the increase of GSH and decrease of ATP
as found in our study are indicative of oxidative stress.
GSH participates in the regulated defense against oxida-
tive stress [48,49], which can be induced by TCDD in
vivo [46,50,51] as well as in vitro [52,53]. ATP was pre-
viously shown to be decreased whereas oxidative stress
increased upon exposure to TCDD in mice [50,51,54].
Besides the AHR-mediated processes, several GPCR
signaling pathway maps as well as other signal transduc-
tion pathway maps were significantly modulated in our
s t u d y( T a b l e3 ) .T h e s em a p si n c l u d em a n yo ft h e1 6
pathway maps uniquely identified by the integrated
‘omics’ analysis, e.g. “G-Proteins mediated regulation
MARK-ERK signaling”, “Beta-adrenergic receptors regu-
lation of ERK”, “G-Protein alpha-i signaling cascades”,
“Rap2A regulation pathway” and “PDGF signaling via
MAPK cascades”. Some of the underlying genes of these
pathways belong to the RAS superfamily, a group of
small GTPases of which their proteins are activated in a
significant fraction of tumors [55,56]. Therefore, these
genes could be of importance in the mechanism for
non-genotoxic carcinogenicity of TCDD. For example,
muscle RAS oncogene homolog (MRAS), related RAS
viral (r-ras) oncogene homolog (RRAS), v-Ki-ras2
Kirsten rat sarcoma viral oncogene homolog (KRAS)
and v-ral simian leukemia viral oncogene homolog B
(RALB) were found to be significantly up-regulated in
our study. Members of the RAS superfamily are posi-
tively regulated by guanine nucleotide exchange factors
(GEFs) [55,56], e.g. son of sevenless (SOS) 1 and ral
guanine nucleotide dissociation stimulator-like 1
(RGL1), which are both significantly up-regulated in the
present study (Figure 1). GEF-activated RAS interact
with downstream effectors, which regulate signaling net-
works that control gene expression and regulation of
cell proliferation, growth arrest, senescence, differentia-
tion, apoptosis and survival [55,56]. As such, SOS1 is
important in the cell growth-regulatory MAPK/ERK
pathway through the activation of RAS family members
[56]. In primary rat hepatocytes SOS has already been
shown to be influenced by TCDD [57] while recently,
Pierre et al. [58] demonstrated that SOS1 is not only
controlled by GPCRs, but also by AHR in TCDD-
exposed HepG2 (Figure 1). In particular, Pierre et al.
[58] found an AHR-dependent increase of SOS1 at the
mRNA and protein level in TCDD-exposed HepG2.
Other prominent pathway maps significantly affected
in HepG2 by TCDD exposure appeared involved in
metabolic processes, mainly relating to amino acid and
lipid metabolism but also vitamin and cofactor metabo-
lism and metabolism of mediators (Table 3).
From the set of 20 essential amino acids at least 11
were significantly decreased after exposure to TCDD
(Table 2). In addition, many genes involved in the
metabolism of these amino acids were down-regulated.
For example, glycine and creatine appeared decreased
and GATM down-regulated which may affect the
synthesis of creatine, an anti-oxidant against ROS, via
two reactions [59]. In the first reaction, ornithine and
guanidinoacetic acid are formed from glycine and argi-
nine by glycine amidinotransferase (GATM). This reac-
tion is the rate-limiting step in creatine biosynthesis
and part of the polyamine metabolism (Figure 2). In
the second reaction, catabolyzed by guanidinoacetate
N-methyltransferase (GAMT), creatine is produced
from guanidinoacetic acid and S-adenosyl-L-
methionine.
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glycine, aspartate and glutamine in the biosynthesis of
nucleotides http://themedicalbiochemistrypage.org/
nucleotide-metabolism.html. Levels of all three amino
acids are decreased upon TCDD-exposure and the gene
in the initial step of the purine metabolism, phosphori-
bosyl pyrophosphate amidotransferase (PPAT) is down-
regulated.
Furthermore, aminoacyl-tRNA biosynthesis is down-
regulated with 12 amino acids decreased and 6 genes
down-regulated, thereby most likely inhibiting global
protein synthesis. In previous rodent studies [8] it was
suggested that genes involved in glutamate, cysteine and
glycine metabolism, may be down-regulated to conserve
the building blocks of GSH, whereas the genes involved
in the synthesis of GSH are up-regulated. Results
Figure 1 RAS gene network developed in MetaCore based on available curated data within the tool. Circles at the top-right of the gene
symbols indicate up- (red) and down-regulation (blue) of the genes for TCDD-exposed HepG2. Direct interactions between nodes are shown
and include the activation (green), inhibition (red) and unspecified (gray) effects. Detailed information on the symbols can be found at http://
www.genego.com/pdf/MC_legend.pdf
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as both GSH and glutathione disulfide (GSSG) are
increased upon TCDD-challenge, with a consistent
increase in gene-expression of glutamate-cysteine ligase
(GCL) which catalyses the production of g-glutamyl-
cysteine, a precursor of GSH (Figure 3).
A further process that is decreased in HepG2 after
exposure to TCDD is the production of N-acetylaspar-
tate (NAA) from aspartate and acetyl-CoA. This reac-
tion is catalyzed by aspartate N-acetyltransferase, which
recently has been identified as NAT8L [60]. This gene is
down-regulated (log2 ratio of -0.83), but not
Figure 2 Polyamine metabolism pathway map in MetaCore including GABA metabolism. Thermometers indicate up- (red) and down-
regulation (blue) of the genes (1) and the metabolites (2) from TCDD-exposed HepG2. Detailed information on the symbols can be found at
http://www.genego.com/pdf/MC_legend.pdf
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protein, but is also found in liver [60,61]. It acts as an
acetyl donor for lipid metabolism. For that, NAA is con-
verted to aspartate and acetate. The acetate released in
this process, may serve as a precursor in the synthesis of
fatty acids by its conversion to acetyl-CoA. The decrease
of NAA corresponds well with the decrease of most
saturated and unsaturated fatty acids in HepG2 exposed
to TCDD. In addition, the gene involved in the first
reaction in the fatty acid synthesis from acetyl CoA, i.e.
acetyl CoA carboxylase (ACACA), is significantly down-
regulated.
Figure 3 Glutathione metabolism pathway map in MetaCore. Thermometers indicate up- (red) and down-regulation (blue) of the genes (1)
and the metabolites (2) from TCDD-exposed HepG2. Detailed information on the symbols can be found at http://www.genego.com/pdf/
MC_legend.pdf
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ine was found to be increased in TCDD-exposed
HepG2. Taurine plays an important role in several phy-
siological functions, such as central nervous system neu-
romodulation, cardiovascular effects, endocrine and
metabolic effects and antioxidant/detoxifying activity. It
is mainly synthesized in liver and brain, either from
cysteine or from methionine, which is first converted to
cysteine [62]. However, the genes involved in taurine
production, were down-regulated or not changed at all
in TCDD-exposed HepG2. Furthermore, taurine is
involved in the conjugation of bile acids by bile acid
CoA:amino acid N-acyltransferase (BAAT) [63]. The
expression of BAAT in this study was down-regulated.
These findings indicate that the increase of taurine in
HepG2 exposed to TCDD is not the result from an
increased taurine production, but rather from a
decreased metabolism. The study of Yanagita et al.[ 6 4 ]
showed that an increase of taurine in HepG2 results in
a decrease of triglycerides and cholesteryl ester. In the
same study it was suggested that acyl-CoA:cholesterol
acyltransferases or sterol O-acyltransferases (SOAT1
and SOAT2), which catalyzes the production of chole-
teryl ester from cholesterol, is inhibited. The decrease of
the triglycerides and cholesteryl ester was also observed
in this study and SOAT2 was down-regulated. In
another study of taurine-exposed HepG2 [65] microar-
ray data analysis showed taurine-mediated gene expres-
sion changes in processes involved in e.g. amino acid
metabolism, fatty acid and lipid metabolism, regulation
of transcription, immune response, cell cycle, apoptosis
and DNA repair. However, from the results of this study
it is unclear in what way taurine plays a role in these
processes.
From the maps identified by cross-omics analysis to
be involved in metabolism of mediators, the polyamine
metabolism map also appeared the number 1 ranked
pathway map in the transcriptomics gene list and
furthermore, is linked to the GABA metabolism [66]
(Figure 2). Both polyamine and GABA metabolism have
a function in cancer-related processes, whereby an
increase of polyamines and/or GABA were observed in
various cancer types [67-71]. Our findings suggest that
TCDD-exposure in HepG2 decreases polyamine meta-
bolism. In the polyamine metabolism putrescine is the
first polyamine produced from which spermidine and
subsequently spermine are produced [67,68]. The pro-
duction of putrescine from ornithine is the rate-limiting
reaction. This reaction is catalyzed by ornithine decar-
boxylase (ODC; DCOR). ODC was significantly down-
r e g u l a t e di nt h i ss t u d y ,a sw e l la sa r g i n a s e1a n d2
(ARG1, ARG2) or GATM that catalyze the preceding
reaction in which ornithine is produced from arginine
or from glycine and arginine, respectively. Spermidine
and N1-acetylspermidine, an N-acetylated polyamine,
were found to be significantly decreased. N1-acetylsper-
midine is an intermediate for the recycling of spermi-
dine into putrescine [67,68]. These in vitro results
correspond well with the in vivo study of Thomas et al.
[28], who showed a decrease in the concentration of
polyamines in mouse liver after exposure to TCDD. In
addition, depletion of polyamines in HepG2 is shown to
prevent apoptosis [66]. In our study, exposure of the
HepG2 cells to TCDD did not affect apoptosis levels,
which were low (< 1%; data not shown).
With regard to the GABA metabolism our results
indicated this metabolism to be enhanced. In the GABA
metabolism, putrescine is used to form GABA through
4-aminobutanal [66]. The latter reaction is catalyzed by
several aldehyde dehydrogenases of which ALDH1A1
(or AL1A1), ALDH1B1 (or AL1B1) and ALDH2 had a
significantly up-regulated gene expression after TCDD
exposure in HepG2. Furthermore, GABA can be formed
from glutamate by glutamate decarboxylase 1 or 2
(GAD1, GAD2), of which GAD1 also has significantly
up-regulated gene expression in this study.
Conclusion
The major result from this study is that TCDD-mediated
‘omics’ responses in HepG2 are comparable with data
from in vivo studies on transcriptomics responses
induced by non-genotoxic carcinogens in rodent liver.
The integrated ‘omics’ analysis resulted in the identifica-
tion of unique pathway maps involved in receptor-
mediated mechanisms. Such mechanisms have been
identified as possible mechanisms for non-genotoxic car-
cinogenicity in vivo [44]; in particular up-regulation of
SOS1 seems to play an important role. This resemblance
with the in vivo situation opens a venue for further devel-
oping HepG2 as an in vitro model for non-genotoxic car-
cinogenicity, by applying cross-omics analysis.
Furthermore, integration of transcriptomics and meta-
bonomics data provided novel insights into response
pathways to TCDD exposure in HepG2, in particular
related to changes in processes involved in amino acid
and lipid metabolism as well as glutathione metabolism
From these metabolic processes the metabolites taurine,
creatine and NAA as well as the genes involved in their
metabolism seem to be important for TCDD-mediated
carcinogenicity as the elevation of taurine and absence/
decrease of creatine and NAA is also observed in
human brain and liver tumors [72-76].
Where novel ‘omics’ technologies such as microRNA
analysis and epigenomics, are becoming increasingly
available, integrated data analysis seems to represent the
w a yf o r w a r di no u rq u e s tf o rb e t t e ru n d e r s t a n d i n g
human health risks in relation to exposure to toxic
agents.
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Cell Culture and Treatment
HepG2 cells were obtained from the American Type
Culture Collection (Rockville, MD). The cells have a
doubling time of about 30 h and grow in clumps. The
HepG2 cells were cultured in 6-well plates for transcrip-
tomics in the presence of minimal essential medium
(MEM) supplemented with 1% non-essential amino
acids, 1% sodium-pyruvate, 2% penicillin/streptomycin
and 10% fetal bovine serum (FBS) (all from Gibco BRL,
Breda, The Netherlands). For metabonomics HepG2
cells were cultured in T75 flasks using MEM plus Gluta-
max supplemented with 1% non-essential amino acids,
1% sodium-pyruvate, 1% penicillin/streptomycin and
10% FBS. The cells were incubated at 37°C and 5% CO2.
When the cells were 80% confluent (density ~1.3 × 10
5
cells/cm
2), the medium was replaced with fresh medium
containing either 10 nM TCDD (CAS no. 1746-01-6;
Cerilliant, Round Rock, TX, USA), or 0.5% DMSO
(Sigma-Aldrich) as a vehicle control. This incubation
concentration dose was demonstrated effective in other
studies [8,9,40,77,78]. For transcriptomics, treatment
was terminated after 48 h by removing the culture med-
ium and immediately adding TRIZOL (Gibco/BRL). For
metabonomics, treatment was stopped after 48 h by
washing the cells several times with ice-cold 0.9% NaCl
and disrupting them by osmotic shock with ice-cold
ultra pure water. The cells were harvested using a cell
scraper and, together with the leaked metabolites, they
were treated ultrasonically to ensure total disruption.
Three and four independent biological replicates were
conducted for transcriptomics and metabonomics,
respectively.
Transcriptomics
Microarray hybridization
Total RNA isolation, target preparation and microarray
hybridization of the Affymetrix Human Genome U133
Plus 2.0 GeneChip arrays were performed as described
by Jennen et al. [40]. The arrays were scanned by means
of an Affymetrix GeneArray scanner resulting in. Nor-
malization quality controls, including scaling factors,
average intensities, present calls, background intensities,
noise, and raw Q values, were within acceptable limits
for all chips. Hybridization controls BioB, BioC, BioD,
and CreX, were called present on all chips and yielded
the expected increases in intensities.
Microarray data analyses
A total of six raw data sets was obtained, which were
re-annotated to the MBNI Custom CDF-files [79]
http://brainarray.mbni.med.umich.edu/Brainarray/Data-
base/CustomCDF/genomic_curated_CDF.asp, RMA
normalized [80] and filtered based on the present,
marginal and absent calls as previously described by
Jennen et al. [40]. The resulting filtered data set, con-
sisting of 10,634 unique genes, was used for further
analyses.
From the intensities of the filtered data set ratios of
treated versus vehicle controls were calculated and sub-
sequently, log2 transformed. Differentially expressed
g e n e s( D E G s )w e r es e l e c t e du s i ng the following criteria:
i) an average log2 ratio of < -0.58 or > 0.58 (i.e. absolute
fold change of 1.5) for the three replicates, ii) same
direction of the log2 ratio for all of three replicates and
iii) a log2 ratio of < -0.26 or > 0.26 (i.e. absolute fold
change of 1.2) for at least two replicates. Furthermore,
significantly modulated DEGs were determined by a
paired Student’sT - t e s tu s i n gp value < 0.05 [1]. FDR
was determined at this p value according to Benjamini
and Hochberg [81].
The transcriptomics data in this publication have been
deposited in EBI’s ArrayExpress http://www.ebi.ac.uk/
microarray-as/ae/ and are accessible through ArrayEx-
press accession number E-MEXP-2817.
Metabonomics
The metabonomics study was performed on two subcel-
lular fractions, the apolar fraction, containing the apolar
metabolites (membranes and intracellular lipids) and the
polar fraction, containing the polar and semi-polar
intracellular metabolites. Extraction of the metabolites
and analysis of the apolar and polar fractions have been
described by Ruiz Aracama et al. [42]. The apolar frac-
tion was analyzed by means of NMR analysis and GC-
MS analysis while on the polar fraction NMR analysis
and LC-MS analysis were performed.
NMR data analysis
Pre-processing of the data and alignment Visual
inspection of the technical replicates (4-fold) of each
sample showed a high degree of reproducibility. The
NMR data were pre-processed and aligned using an in-
house developed program [82].
Normalization The aligned fingerprint data in the form
of generated spreadsheets were normalized by using fac-
tors obtained from the scaling on the phospholipids sig-
nals of the
1H NMR spectra of the apolar fraction.
Statistical analysis The normalized spreadsheets were
then subjected to statistical analysis using Genemaths
XT http://www.applied-maths.com/genemaths/gene-
maths.htm. Standard analysis entailed performing an
ANOVA or Student Test (p < 0.01 after log2 transfor-
mation) combined with a PCA. From this type of figure
a selection of peak loadings - underlying the separation
in the PCA - could be exported. Only differences with a
log2 ratio of < -0.26 or > 0.26 (i.e. absolute fold change
of 1.2) were taken into account.
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The identification was done by using commercial stan-
dards and/or from literature and databases.
MS data analysis
Pre-processing of the data and alignment Visual
inspection of the technical replicates (4-fold) of each
sample showed a high degree of reproducibility. The
GC-MS and LC-MS data are pre-processed and aligned
using MetAlign [83]http://www.metalign.nl.
Normalization
LC-MS dataset The aligned fingerprint data of the
polar fraction dataset, in the form of generated spread-
sheets, were normalized by using the phospholipids scal-
ing factors obtained from the
1H NMR spectra of the
apolar fraction.
GC-MS dataset The identified peaks of GC-MS chro-
matograms were manually integrated. Normalization of
this fraction was done by scaling to the raw values of
the integrals of docosahexaenoic and arachidonic methyl
esters.
Statistical analysis The normalized spreadsheets of
both datasets were subjected to statistical analysis using
Genemaths XT. Standard analysis entailed performing a
log2 transformation, an ANOVA or Student Test (p <
0.05 or p < 0.01, depending on the fraction) combined
with a PCA. From this type of figure a selection of peak
loadings - underlying the separation in the PCA - can
be exported. Only differences with a log2 ratio of <
-0.26 or > 0.26 (i.e. absolute fold change of 1.2) were
taken into account.
Identification of metabolites
Further analysis and identification was facilitated by
using GM2MS, an application of MetAlign that re-cre-
ates “new chromatograms” containing only the peaks
exported from the PCA selection. Polar metabolites
were identified with commercial standards, with FT-MS/
MS analysis and using databases. Fatty acids were iden-
tified using databases, the eluting order of the peaks and
the NIST library.
Pathway analyses
For the pathway analysis the significant DEGs and meta-
bolites were uploaded into MetaCore (GeneGo, San
Diego, CA) for identifying the involvement of these
genes or metabolites in specific cellular pathway maps
by overrepresentation analyses compared to the total
amount of objects involved in the particular maps. As a
first step, the transcriptomics and metabonomics data
were analyzed separately. In the analysis the filtered data
set was used as background list for the transcriptomics
data. For the analysis of the metabonomics data no
background list could be used. Pathway maps with a p
v a l u e<0 . 0 5a n da tl e a s tt w o genes or metabolites pre-
sent were considered significantly modulated. Within
MetaCore FDRs were determined at this p value accord-
ing to Benjamini and Hochberg [81].
As a second step, the individual gene and metabolite
lists were combined for an integrated analysis of the
transcriptomics and metabonomics responses, i.e. for
identifying pathway maps in which both genes as well as
metabolites are involved. The pathway analysis with the
combined list was done in the same fashion as in the
first step. In this analysis no background list could be
used and pathway maps with a p value < 0.05 and at
least two genes or metabolites present were considered
significantly modulated. FDR was determined at this p
value according to Benjamini and Hochberg [81]. From
these significantly modified pathway maps, the maps
containing both significant DEGs as well as significantly
modulated metabolites were further examined.
Finally, the transcriptomics and metabonomics data
could be visualized on the pathway maps or on net-
works created in MetaCore based on the significant
pathway maps using the curated information within the
pathway tool.
Additional material
Additional file 1: DEGs of TCDD-exposed HepG2. Expression data
(log2 ratios) of the 1,048 differentially expressed genes of TCDD-exposed
HepG2. Statistical significance (p value < 0.05) is indicated.
Additional file 2: Result of MetaCore analyses using transcriptomics
and metabonomics data. A complete list of significantly modulated
maps (p value < 0.05 and at least two genes or metabolites present) per
MetaCore analysis of the TCDD-exposed HepG2. Common maps
between the transcriptomics and metabonomics analysis are indicated.
Additional file 3: Result of MetaCore analyses using integrated data.
A complete list of significantly modulated maps (p value < 0.05 and at
least two genes or metabolites present) retrieved by integrated analysis
in MetaCore containing both significant DEGs as well as significantly
modulated metabolites.
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